Year: 2021
Type: review
Abstract: Over the last decade, important clinical benefits have been achieved in cancer patients by using drug-targeting strategies. Nevertheless, drug resistance is still a major problem in most cancer therapies. Epithelial-mesenchymal plasticity (EMP) and tumour microenvironment have been described as limiting factors for effective treatment in many cancer types. Moreover, epithelial-to-mesenchymal transition (EMT) has also been associated with therapy resistance in many different preclinical models, although limited evidence has been obtained from clinical studies and clinical samples. In this review, we particularly deepen into the mechanisms of which intermediate epithelial/mesenchymal (E/M) states and its interconnection to microenvironment influence therapy resistance. We also describe how the use of bioinformatics and pharmacogenomics will help to figure out the biological impact of the EMT on drug resistance and to develop novel pharmacological approaches in the future.
Source: Archives of Toxicology
Institutions: Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, Ruđer Bošković Institute, Tel Aviv University, Universidade da Coruña, Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña, Servicio Gallego de Salud
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,480
Awards: G1353779963, Eficacia de nuevos antitumorales dirigidos contra el cáncer de colon metastásico, G2500401905, G2639201810, G2786899834, Nuevos compuestos inhibidores de acción antitumoral: validación y estudio del mecanismo en el tratamiento contra el cáncer, Drug-induced epithelial-mesenchymal transition in ovarian cancer therapy, G498438737, G5132640529, G5949309902, G5955501538, Onco-proteogenómica personalizada aplicada a hemopatías malignas e inmunomodulación: desarrollo y uso de métodos bioinformáticos para búsqueda de marcadores, predictores de riesgo y dianas en pacientes y donantes., G7685134749, G7723768703
OpenAlex ID: W3161782839
